BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, FiscalAI reports. BioNexus Gene Lab had a negative return on equity of 32.92% and a negative net margin of 82.38%. The company had revenue of $0.05 million for the quarter.
BioNexus Gene Lab Stock Performance
Shares of BGLC opened at $0.68 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.28 and a current ratio of 6.08. The company has a market capitalization of $1.99 million, a price-to-earnings ratio of -0.54 and a beta of 4.28. The company’s 50 day simple moving average is $1.15 and its 200 day simple moving average is $1.81. BioNexus Gene Lab has a 1 year low of $0.62 and a 1 year high of $4.97.
Analysts Set New Price Targets
Separately, Weiss Ratings lowered BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company currently has an average rating of “Sell”.
View Our Latest Research Report on BGLC
BioNexus Gene Lab Company Profile
BioNexus Gene Lab Corp. is a Malaysia-focused company with businesses in medical diagnostics and chemical distribution. Through its laboratory operations, it provides molecular and genetic testing services to support healthcare assessment and decision-making. The company also distributes industrial and specialty chemicals through its subsidiary, Chemrex Corporation. Its products serve business customers in sectors that use chemicals in manufacturing and related applications. BioNexus Gene Lab’s operations are primarily based in Malaysia.
Read More
- Five stocks we like better than BioNexus Gene Lab
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.
